Vir antibody drug aimed at influenza A fails in clinical trial
Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a 3,000-person clinical trial.
Volunteers who received the highest dose of the drug, known as Vir-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.
Read Original Article: Vir antibody drug aimed at influenza A fails in clinical trial »
